#Herceptin | Explore Tumblr posts and blogs

biopractify · 2 days ago

Text

🧬 How Bioinformatics is Revolutionizing Pharma & Drug Discovery 🚀

🔬 Bioinformatics is changing the way we develop medicines. From AI-driven drug discovery to genomics-based precision medicine, biotech is making healthcare smarter, faster, and more personalized. But how exactly is it transforming the pharma industry? Let’s explore!

📖 Keep scrolling to uncover how AI, data science, and bioinformatics are shaping the future of medicine!

✨ The Impact of Bioinformatics in Drug Discovery

🔹 1. Finding the Right Drug Targets Faster

📌 Old Way: Scientists spent years identifying potential drug targets. 🚀 Now: AI & bioinformatics analyze vast genomic datasets to find disease-related genes in hours!

💡 Example: AI-driven analysis helped identify key targets for cancer immunotherapy drugs like Keytruda (pembrolizumab).

🔹 2. Computational Drug Design & AI-Powered Screening

💊 Why waste years testing thousands of compounds?

Bioinformatics speeds up drug discovery through virtual screening & molecular simulations.

AI models predict how different drugs will interact with the body.

🔥 Pfizer used AI-driven bioinformatics to speed up the development of COVID-19 antivirals!

🔹 3. Personalized Medicine & Biomarker Discovery

✨ Not all treatments work for everyone. Bioinformatics makes medicine more precise!

Identifies genetic markers for disease risk.

Develops customized treatments for cancer & genetic disorders.

Predicts how patients will respond to a drug before prescribing it.

💡 Example: The breast cancer drug Herceptin was developed using bioinformatics to target HER2-positive patients.

🔹 4. CRISPR Gene Editing & Next-Gen Therapies

🧬 Bioinformatics guides CRISPR gene editing, helping scientists:

Design gene therapies for rare genetic disorders.

Reduce off-target mutations for safer treatments.

Improve DNA sequencing for precision medicine.

🔥 Companies like Intellia Therapeutics are using AI-powered bioinformatics for gene editing!

🔹 5. AI-Optimized Clinical Trials & Drug Repurposing

👩‍⚕️ Clinical trials cost billions. Bioinformatics helps optimize them!

Predicts side effects using AI.

Finds new uses for existing drugs (like how Remdesivir was repurposed for COVID-19).

Helps pharma companies save time & money while improving success rates.

💡 Example: AI-driven bioinformatics helped repurpose existing drugs for rare diseases!

🚀 The Future of Bioinformatics in Pharma

💡 The biotech revolution is just getting started! Expect to see: ✅ AI-powered drug design in real time. ✅ Nanomedicine & regenerative therapies. ✅ Affordable personalized medicine.

✨ What excites you most about the future of bioinformatics? Drop your thoughts in the comments! 💬👇

#Bioinformatics #PharmaTech #DrugDiscovery #AI #MedicalScience #biopractify

1 note · View note

femalesurgeonuae · 5 days ago

Text

Breast Cancer Treatment in Dubai: Comprehensive Options for Hope and Healing

Breast cancer is one of the most common cancers affecting women worldwide, and Dubai has emerged as a hub for advanced medical care, offering cutting-edge technologies and compassionate support for patients. With its world-class healthcare facilities and a team of skilled professionals, Dubai provides a broad spectrum of treatment options tailored to individual needs. Whether you're seeking early-stage treatment or advanced therapies, this guide will walk you through the comprehensive breast cancer treatment in dubai.

Understanding Breast Cancer and Its Diagnosis

Breast cancer occurs when abnormal cells in the breast begin to grow uncontrollably. These cancerous cells can form lumps or spread to other parts of the body if left untreated. Early detection is key, and Dubai's hospitals emphasize proactive measures such as regular mammograms, clinical breast exams, and self-checks.

Diagnostic Tools Available in Dubai

Dubai’s healthcare institutions are equipped with state-of-the-art diagnostic tools, including:

Mammography: A low-dose X-ray to detect lumps or abnormalities.

Ultrasound: Used to evaluate any suspicious findings from a mammogram.

MRI Scans: Provides a detailed image for detecting subtle changes in breast tissue.

Biopsy: Extracting a small sample of tissue for testing to confirm the presence of cancer.

The accuracy and precision of these diagnostic tools ensure early detection, which plays a pivotal role in successful treatment outcomes.

Treatment Options for Breast Cancer in Dubai

Dubai’s medical facilities offer a holistic approach to breast cancer treatment, combining advanced technology with compassionate care. Treatment plans are customized based on the stage of cancer, patient health, and personal preferences.

1. Surgery: The First Line of Defense

Surgery is often the first step in breast cancer treatment, aimed at removing cancerous tissues. Dubai offers the following surgical options:

Lumpectomy: Removal of the tumor while preserving most of the breast.

Mastectomy: Removal of one or both breasts, depending on the extent of cancer.

Reconstructive Surgery: Performed after mastectomy to restore the breast’s appearance using implants or natural tissues.

Dubai's skilled surgeons use minimally invasive techniques whenever possible, ensuring quicker recovery and better cosmetic outcomes.

2. Radiation Therapy

Radiation therapy is used to target and destroy cancer cells after surgery. Dubai’s hospitals employ advanced radiation technologies like image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), which precisely target cancer cells while sparing healthy tissue.

3. Chemotherapy

Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells. In Dubai, patients receive personalized chemotherapy plans based on the type and stage of cancer. Treatment can be delivered through:

Intravenous injections.

Oral medications.

Oncology centers in Dubai prioritize patient comfort, offering services such as private infusion rooms and round-the-clock medical support.

4. Hormone Therapy

For hormone-sensitive breast cancers, hormone therapy is an effective treatment. This involves medications that block hormones like estrogen or progesterone, which fuel cancer growth. Hormone therapy is often used in combination with other treatments to maximize effectiveness.

5. Targeted Therapy

Targeted therapy involves drugs designed to attack specific proteins or genes that contribute to cancer growth. Dubai’s hospitals are at the forefront of using drugs like Herceptin for HER2-positive breast cancers, ensuring precision in treatment and fewer side effects.

6. Immunotherapy

Dubai is embracing immunotherapy as an innovative treatment option. It harnesses the body’s immune system to identify and fight cancer cells. This cutting-edge approach offers hope to patients with aggressive or advanced-stage cancers.

Supportive Care and Rehabilitation

Breast cancer treatment goes beyond medical interventions. Emotional and physical support are vital for recovery, and Dubai provides robust support systems, including:

Counseling Services: To help patients and families navigate the emotional challenges of cancer.

Physiotherapy: Assists in regaining strength and mobility after surgery or other treatments.

Support Groups: Encourages patients to share their experiences and find solidarity with others undergoing similar journeys.

Dubai’s hospitals also focus on post-treatment wellness, offering nutrition counseling, fitness programs, and mental health support to promote overall well-being.

World-Class Facilities for Breast Cancer Treatment in Dubai

Dubai is home to some of the best oncology centers, including the Dubai Hospital, Mediclinic City Hospital, and American Hospital Dubai. These institutions boast:

Multidisciplinary teams of oncologists, surgeons, and radiologists.

Advanced medical technologies such as robotic surgery and AI-assisted diagnostics.

Personalized treatment plans to ensure the best possible outcomes.

Moreover, Dubai’s commitment to medical excellence attracts top global professionals, ensuring that patients receive world-class care without having to travel abroad.

Why Choose Dubai for Breast Cancer Treatment?

1. Cutting-Edge Technology

From AI-driven diagnostic tools to advanced treatment options like proton therapy, Dubai is at the forefront of medical innovation.

2. Highly Skilled Specialists

Dubai’s hospitals house some of the world’s leading oncologists and breast cancer specialists, ensuring you’re in the best hands.

3. Multilingual Support

Dubai’s diverse population means that medical professionals are well-versed in multiple languages, ensuring clear communication for international patients.

4. Patient-Centric Care

The holistic approach in Dubai emphasizes patient comfort, emotional well-being, and a seamless medical experience.

Early Detection Saves Lives

Breast cancer treatment in Dubai is highly effective, but early detection remains the cornerstone of successful outcomes. Regular check-ups and self-awareness are vital. Look for symptoms such as lumps, changes in breast shape, or unexplained pain, and consult a specialist immediately if you notice anything unusual.

Final Thoughts

Breast cancer treatment hospitals in Dubai combines innovation, expertise, and empathy to provide hope and healing to patients. With world-class facilities and personalized care plans, Dubai has established itself as a trusted destination for breast cancer treatment. Remember, breast cancer is treatable, especially when detected early, so don’t delay seeking professional care.

#Breast Cancer Treatment in Dubai

0 notes

kkumarsblog · 17 days ago

Text

Trastuzumab Biosimilars Market Insights, 2024

Trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer, has revolutionized cancer care by targeting the HER2 receptor, which is overexpressed in a subset of breast cancer cases. As the demand for more affordable treatments grows, trastuzumab biosimilars have emerged as a viable solution, offering improved access to essential cancer therapies while reducing healthcare costs.

Market Dynamics

The global trastuzumab biosimilars market pipeline is experiencing rapid growth, driven by the increasing prevalence of HER2-positive breast cancer and the cost-effectiveness of biosimilars. Breast cancer remains the most commonly diagnosed cancer worldwide, according to the World Health Organization (WHO), intensifying the need for accessible treatment options, particularly in emerging markets.

Biosimilars provide a cost-efficient alternative to Roche’s originator product, Herceptin, without compromising efficacy or safety. Following the expiration of Herceptin’s patents, several biosimilars have entered the market, including Ogivri (Mylan/Biocon), Kanjinti (Amgen), and Ontruzant (Samsung Bioepis), which are contributing to widespread adoption and affordability.

Competitive Landscape

The trastuzumab biosimilars market is highly competitive, with several companies striving for a significant market share. Key players include:

Biocon and Mylan: Their biosimilar Ogivri has been approved in major regions like the U.S. and Europe, offering substantial cost savings.

Amgen: Kanjinti, Amgen's biosimilar, is FDA- and EMA-approved and gaining significant market acceptance.

Samsung Bioepis: In collaboration with Merck, Samsung Bioepis developed Ontruzant, a prominent biosimilar in the market.

Celltrion: With a robust biosimilar portfolio that includes Truxima and Herzuma, Celltrion is strengthening its foothold in the trastuzumab segment.

Challenges and Opportunities

While the adoption of trastuzumab biosimilars is steadily rising, challenges remain. These include regulatory complexities, limited market access, and reluctance among some physicians and patients to switch from branded products. However, as more biosimilars receive approvals and clinical experience with these therapies increases, adoption rates are expected to grow, creating significant opportunities.

Future Outlook

The trastuzumab biosimilars market is anticipated to expand significantly by 2024, driven by increased product approvals, reduced costs, and rising demand for advanced cancer therapies. With the development of new biosimilars, competition is set to intensify, benefiting both patients and healthcare providers. The future of trastuzumab biosimilars is bright, enhancing global access to targeted cancer treatments.

Related Reports by DelveInsight

Aneurysmal Subarachnoid Hemorrhage Market

Angelman Syndrome Market

Autoimmune Pulmonary Alveolar Proteinosis Market

Cardiovascular Calcification Market

Charcot Marie Tooth Disease Market

Chronic Focal Epilepsy Market

Crispr Therapies- Pipeline Insights Market

Cytokine Release Syndrome Market

Frontotemporal Dementia Market

Glabellar Frown Lines Market

Graves Ophthalmopathy Market

Icos-next Generation Immunotherapy Market

Invasive Pneumococcal Disease Market

Lipodystrophy Market

Nasolabial Fold Market

Natural Killer T Cell Lymphoma Market

About DelveInsight

DelveInsight is a global leader in market research and consulting, specializing in the healthcare and life sciences sectors. By providing detailed market insights, DelveInsight supports pharmaceutical, biotechnology, and medical device companies in making informed and strategic decisions within a competitive landscape.

Contact Information Kanishk Kumar Email: [email protected]

0 notes

roshankumar7904800 · 1 month ago

Text

Cancer Monoclonal Antibodies Market

Cancer Monoclonal Antibodies Market Size, Share, Trends: Roche Holding AG Leads

Increasing Acceptance of Combo Treatments

Market Overview:

The global Cancer Monoclonal Antibodies Market is anticipated to grow at a CAGR of 10.2% between USD 43.8 billion in 2022 and USD 95.6 billion by 2031. Throughout the forecast period, North America is expected to dominate the market. Growing cancer incidence worldwide, advancements in monoclonal antibody technology, and a growing demand for personalised cancer treatments are driving a significant expansion in the Cancer Monoclonal Antibodies Market. Monoclonal antibodies have grown in importance as a component of cancer treatment programs because they are more effective and have fewer side effects than conventional chemotherapy. The industry is driven by ongoing R&D projects, broad applicability across various illness types, and increased investment in precision medicine techniques.

DOWNLOAD FREE SAMPLE

Market Trends:

Using monoclonal antibodies in conjunction with other cancer therapies to improve effectiveness and get over drug resistance. In the oncology domain, monoclonal antibodies combined with other cancer treatments are becoming very popular. This method creates more powerful and effective cancer-fighting regimens by combining the targeted character of monoclonal antibodies with traditional treatments such as chemotherapy, radiation, or other immunotherapies. Combining treatments might possibly overcome drug resistance mechanisms, increase tumor cell killing, and improve general therapy results. For many different kinds of cancer, for example, combining immune checkpoint inhibitors with focused monoclonal antibodies has shown encouraging effects.

Market Segmentation:

High incidence rates and recognized treatment strategies drive the section of the Cancer Monoclonal Antibodies Market dedicated to breast cancer application. Driven by elements like high worldwide incidence rates, well-established treatment regimens, and the availability of many authorized monoclonal antibody therapeutics, the segment on breast cancer applications has a prominent position in the Cancer Monoclonal Antibodies Market. With a projected 2.3 million new cases detected in 2020 according to the World Health Organization, breast cancer continues to be among the most often occurring cancer types globally. Increased research and development in this field is a result of monoclonal antibodies such as trastuzumab (Herceptin) being successful in treating HER2-positive breast cancer.

Market Key Players:

The Cancer Monoclonal Antibodies Market is highly competitive, with major players focusing on research and development investments to keep their market share and increase the range of products. Key companies such as Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, AbbVie Inc., Sanofi S.A., and GlaxoSmithKline plc dominate the market.

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market research #market trends

0 notes

indianph · 2 months ago

Text

Trastuzumab is formulated as a targeted therapy. It is approved for treating patients with HER2+ gastric, colorectal, lung, and metastatic breast cancer. It works by attaching to HER2 receptors on cancer cells. It stops their growth. To inquire Trastuzumab price and availability-related information, get in touch with The Indian Pharma (TIP). We specialize in facilitating the legal supply of this medicine to patients across the world. We are the WHO-GDP-certified supplier of hard-to-access medicines from India. Kindly get in touch with us via Call/WhatsApp: +91 8130290915 to know more about how you can buy trastuzumab 440 mg injection.

#Trastuzumab price

0 notes

sunaleisocial · 2 months ago

Text

Introducing MIT HEALS, a life sciences initiative to address pressing health challenges

New Post has been published on https://sunalei.org/news/introducing-mit-heals-a-life-sciences-initiative-to-address-pressing-health-challenges/

Introducing MIT HEALS, a life sciences initiative to address pressing health challenges

At MIT, collaboration between researchers working in the life sciences and engineering is a frequent occurrence. Under a new initiative launched last week, the Institute plans to strengthen and expand those collaborations to take on some of the most pressing health challenges facing the world.

The new MIT Health and Life Sciences Collaborative, or MIT HEALS, will bring together researchers from all over the Institute to find new solutions to challenges in health care. HEALS will draw on MIT’s strengths in life sciences and other fields, including artificial intelligence and chemical and biological engineering, to accelerate progress in improving patient care.

“As a source of new knowledge, of new tools and new cures, and of the innovators and the innovations that will shape the future of biomedicine and health care, there is just no place like MIT,” MIT President Sally Kornbluth said at a launch event last Wednesday in Kresge Auditorium. “Our goal with MIT HEALS is to help inspire, accelerate, and deliver solutions, at scale, to some of society’s most urgent and intractable health challenges.”

The launch event served as a day-long review of MIT’s historical impact in the life sciences and a preview of what it hopes to accomplish in the future.

“The talent assembled here has produced some truly towering accomplishments. But also — and, I believe, more importantly — you represent a deep well of creative potential for even greater impact,” Kornbluth said.

Massachusetts Governor Maura Healey, who addressed the filled auditorium, spoke of her excitement about the new initiative, emphasizing that “MIT’s leadership and the work that you do are more important than ever.”

“One of things as governor that I really appreciate is the opportunity to see so many of our state’s accomplished scientists and bright minds come together, work together, and forge a new commitment to improving human life,” Healey said. “It’s even more exciting when you think about this convening to think about all the amazing cures and treatments and discoveries that will result from it. I’m proud to say, and I really believe this, this is something that could only happen in Massachusetts. There’s no place that has the ecosystem that we have here, and we must fight hard to always protect that and to nurture that.”

A history of impact

MIT has a long history of pioneering new fields in the life sciences, as MIT Institute Professor Phillip Sharp noted in his keynote address. Fifty years ago, MIT’s Center for Cancer Research was born, headed by Salvador Luria, a molecular biologist and a 1975 Nobel laureate.

That center helped to lead the revolutions in molecular biology, and later recombinant DNA technology, which have had significant impacts on human health. Research by MIT Professor Robert Weinberg and others identifying cancer genes has led the development of targeted drugs for cancer, including Herceptin and Gleevec.

In 2007, the Center for Cancer Research evolved into the Koch Institute for Integrative Cancer Research, whose faculty members are divided evenly between the School of Science and the School of Engineering, and where interdisciplinary collaboration is now the norm.

While MIT has long been a pioneer in this kind of collaborative health research, over the past several years, MIT’s visiting committees reported that there was potential to further enhance those collaborations, according to Nergis Mavalvala, dean of MIT’s School of Science.

“One of the very strong themes that emerged was that there’s an enormous hunger among our colleagues to collaborate more. And not just within their disciplines and within their departments, but across departmental boundaries, across school boundaries, and even with the hospitals and the biotech sector,” Mavalvala told MIT News.

To explore whether MIT could be doing more to encourage interdisciplinary research in the life sciences, Mavalvala and Anantha Chandrakasan, dean of the School of Engineering and MIT’s chief innovation and strategy officer, appointed a faculty committee called VITALS (Vision to Integrate, Translate and Advance Life Sciences).

That committee was co-chaired by Tyler Jacks, the David H. Koch Professor of Biology at MIT and a member and former director of the Koch Institute, and Kristala Jones Prather, head of MIT’s Department of Chemical Engineering.

“We surveyed the faculty, and for many people, the sense was that they could do more if there were improved mechanisms for interaction and collaboration. Not that those don’t exist — everybody knows that we have a highly collaborative environment at MIT, but that we could do even more if we had some additional infrastructure in place to facilitate bringing people together, and perhaps providing funding to initiate collaborative projects,” Jacks said before last week’s launch.

These efforts will build on and expand existing collaborative structures. MIT is already home to a number of institutes that promote collaboration across disciplines, including not only the Koch Institute but also the McGovern Institute for Brain Research and the Picower Institute for Learning and Memory.

“We have some great examples of crosscutting work around MIT, but there’s still more opportunity to bring together faculty and researchers across the Institute,” Chandrakasan said before the launch event. “While there are these great individual pieces, we can amplify those while creating new collaborations.”

Supporting science

In her opening remarks on Wednesday, Kornbluth announced several new programs designed to support researchers in the life sciences and help promote connections between faculty at MIT, surrounding institutions and hospitals, and companies in the Kendall Square area.

“A crucial part of MIT HEALS will be finding ways to support, mentor, connect, and foster community for the very best minds, at every stage of their careers,” she said.

With funding provided by Noubar Afeyan PhD ’87, an executive member of the MIT Corporation and founder and CEO of Flagship Pioneering, MIT HEALS will offer fellowships for graduate students interested in exploring new directions in the life sciences.

Another key component of MIT HEALS will be the new Hood Pediatric Innovation Hub, which will focus on development of medical treatments specifically for children. This program, established with a gift from the Charles H. Hood Foundation, will be led by Elazer Edelman, a cardiologist and the Edward J. Poitras Professor in Medical Engineering and Science at MIT.

“Currently, the major market incentives are for medical innovations intended for adults — because that’s where the money is. As a result, children are all too often treated with medical devices and therapies that don’t meet their needs, because they’re simply scaled-down versions of the adult models,” Kornbluth said.

As another tool to help promising research projects get off the ground, MIT HEALS will include a grant program known as the MIT-MGB Seed Program. This program, which will fund joint research projects between MIT and Massachusetts General Hospital/Brigham and Women’s Hospital, is being launched with support from Analog Devices, to establish the Analog Devices, Inc. Fund for Health and Life Sciences.

Additionally, the Biswas Family Foundation is providing funding for postdoctoral fellows, who will receive four-year appointments to pursue collaborative health sciences research. The details of the fellows program will be announced in spring 2025.

“One of the things we have learned through experience is that when we do collaborative work that is cross-disciplinary, the people who are actually crossing disciplinary boundaries and going into multiple labs are students and postdocs,” Mavalvala said prior to the launch event. “The trainees, the younger generation, are much more nimble, moving between labs, learning new techniques and integrating new ideas.”

Revolutions

Discussions following the release of the VITALS committee report identified seven potential research areas where new research could have a big impact: AI and life science, low-cost diagnostics, neuroscience and mental health, environmental life science, food and agriculture, the future of public health and health care, and women’s health. However, Chandrakasan noted that research within HEALS will not be limited to those topics.

“We want this to be a very bottom-up process,” he told MIT News. “While there will be a few areas like AI and life sciences that we will absolutely prioritize, there will be plenty of room for us to be surprised on those innovative, forward-looking directions, and we hope to be surprised.”

At the launch event, faculty members from departments across MIT shared their work during panels that focused on the biosphere, brains, health care, immunology, entrepreneurship, artificial intelligence, translation, and collaboration. The program, which was developed by Amy Keating, head of the Department of Biology, and Katharina Ribbeck, the Andrew and Erna Viterbi Professor of Biological Engineering, also included a spoken-word performance by Victory Yinka-Banjo, an MIT senior majoring in computer science and molecular biology.

In her performance, called “Systems,” Yinka-Banjo urged the audience to “zoom out,” look at systems in their entirety, and pursue collective action.

“To be at MIT is to contribute to an era of infinite impact. It is to look beyond the microscope, zooming out to embrace the grander scope. To be at MIT is to latch onto hope so that in spite of a global pandemic, we fight and we cope. We fight with science and policy across clinics, academia, and industry for the betterment of our planet, for our rights, for our health,” she said.

In a panel titled “Revolutions,” Douglas Lauffenburger, the Ford Professor of Engineering and one of the founders of MIT’s Department of Biological Engineering, noted that engineers have been innovating in medicine since the 1950s, producing critical advances such as kidney dialysis, prosthetic limbs, and sophisticated medical imaging techniques.

MIT launched its program in biological engineering in 1998, and it became a full-fledged department in 2005. The department was founded based on the concept of developing new approaches to studying biology and developing potential treatments based on the new advances being made in molecular biology and genomics.

“Those two revolutions laid the foundation for a brand new kind of engineering that was not possible before them,” Lauffenburger said.

During that panel, Jacks and Ruth Lehmann, director of the Whitehead Institute for Biomedical Research, outlined several interdisciplinary projects underway at the Koch Institute and the Whitehead Institute. Those projects include using AI to analyze mammogram images and detect cancer earlier, engineering drought-resistant plants, and using CRISPR to identify genes involved in toxoplasmosis infection.

These examples illustrate the potential impact that can occur when “basic science meets translational science,” Lehmann said.

“I’m really looking forward to HEALS further enlarging the interactions that we have, and I think the possibilities for science, both at a mechanistic level and understanding the complexities of health and the planet, are really great,” she said.

The importance of teamwork

To bring together faculty and students with common interests and help spur new collaborations, HEALS plans to host workshops on different health-related topics. A faculty committee is now searching for a director for HEALS, who will coordinate these efforts.

Another important goal of the HEALS initiative, which was the focus of the day’s final panel discussion, is enhancing partnerships with Boston-area hospitals and biotech companies.

“There are many, many different forms of collaboration,” said Anne Klibanski, president and CEO of Mass General Brigham. “Part of it is the people. You bring the people together. Part of it is the ideas. But I have found certainly in our system, the way to get the best and the brightest people working together is to give them a problem to solve. You give them a problem to solve, and that’s where you get the energy, the passion, and the talent working together.”

Robert Langer, the David H. Koch Institute Professor at MIT and a member of the Koch Institute, noted the importance of tackling fundamental challenges without knowing exactly where they will lead. Langer, trained as a chemical engineer, began working in biomedical research in the 1970s, when most of his engineering classmates were going into jobs in the oil industry.

At the time, he worked with Judah Folkman at Boston Children’s Hospital on the idea of developing drugs that would starve tumors by cutting off their blood supply. “It took many, many years before those would [reach patients],” he says. “It took Genentech doing great work, building on some of the things we did that would lead to Avastin and many other drugs.”

Langer has spent much of his career developing novel strategies for delivering molecules, including messenger RNA, into cells. In 2010, he and Afeyan co-founded Moderna to further develop mRNA technology, which was eventually incorporated into mRNA vaccines for Covid.

“The important thing is to try to figure out what the applications are, which is a team effort,” Langer said. “Certainly when we published those papers in 1976, we had obviously no idea that messenger RNA would be important, that Covid would even exist. And so really it ends up being a team effort over the years.”

0 notes

jcmarchi · 2 months ago

Text

Introducing MIT HEALS, a life sciences initiative to address pressing health challenges

New Post has been published on https://thedigitalinsider.com/introducing-mit-heals-a-life-sciences-initiative-to-address-pressing-health-challenges/

Introducing MIT HEALS, a life sciences initiative to address pressing health challenges

The launch event served as a day-long review of MIT’s historical impact in the life sciences and a preview of what it hopes to accomplish in the future.

A history of impact

Supporting science

“A crucial part of MIT HEALS will be finding ways to support, mentor, connect, and foster community for the very best minds, at every stage of their careers,” she said.

Revolutions

In her performance, called “Systems,” Yinka-Banjo urged the audience to “zoom out,” look at systems in their entirety, and pursue collective action.

“Those two revolutions laid the foundation for a brand new kind of engineering that was not possible before them,” Lauffenburger said.

These examples illustrate the potential impact that can occur when “basic science meets translational science,” Lehmann said.

The importance of teamwork

Another important goal of the HEALS initiative, which was the focus of the day’s final panel discussion, is enhancing partnerships with Boston-area hospitals and biotech companies.

0 notes

0healthcare1 · 2 months ago

Link

0 notes

pavankalnad · 3 months ago

Text

Vivitra 440 mg is a biosimilar of trastuzumab, a monoclonal antibody used to treat HER2-positive breast cancer and other cancers. It targets the HER2 receptor, which is overexpressed in some cancer cells, slowing or stopping their growth. Produced by Zydus Cadila, Vivitra offers an affordable alternative to its originator drug, Herceptin.

#onlinemedicine #buysm

1 note · View note

credenceresearchdotblog · 3 months ago

Text

The Oncology Biosimilars Market is projected to grow from USD 4725 million in 2024 to an estimated USD 23341.41 million by 2032, with a compound annual growth rate (CAGR) of 22.1% from 2024 to 2032. The oncology biosimilars market is rapidly emerging as a key segment in the biopharmaceutical industry. With increasing cases of cancer globally and the rising costs of innovative biologics, oncology biosimilars offer a cost-effective alternative while ensuring similar safety and efficacy profiles. This article delves into the market dynamics, trends, challenges, and future prospects of oncology biosimilars.

Browse the full report https://www.credenceresearch.com/report/oncology-biosimilars-market

Understanding Oncology Biosimilars

Biosimilars are biologic medical products that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, efficacy, or quality. In oncology, biosimilars address various cancers such as breast cancer, colorectal cancer, non-small cell lung cancer, and lymphoma. They replicate biologics like monoclonal antibodies and growth factors used in cancer treatment and supportive care.

Market Growth Drivers

1. Rising Cancer Incidence: According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with an estimated 20 million new cases in 2022 alone. This growing disease burden amplifies the demand for cost-effective treatment options, making oncology biosimilars a critical component of cancer care.

2. Cost-Effectiveness: Biosimilars are priced approximately 15-30% lower than their reference biologics, offering significant savings for healthcare systems and patients. This affordability is particularly impactful in low- and middle-income countries where access to expensive biologics is limited.

3. Patent Expirations: Several blockbuster oncology biologics, including trastuzumab (Herceptin) and bevacizumab (Avastin), have lost patent protection in recent years. This has paved the way for the entry of biosimilars, driving market competition and adoption.

4. Regulatory Support: Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established clear guidelines for the approval of biosimilars, encouraging pharmaceutical companies to invest in their development.

Key Market Trends

1. Expanding Product Portfolio: The oncology biosimilars market is witnessing an expansion in product offerings. Biosimilars for blockbuster drugs such as rituximab, pegfilgrastim, and cetuximab are gaining traction, with multiple players entering the space.

2. Increasing Approvals and Launches: Over the past decade, the FDA and EMA have approved numerous oncology biosimilars, including biosimilars for trastuzumab (e.g., Ogivri, Herzuma) and bevacizumab (e.g., Zirabev, Mvasi). These approvals have bolstered the market and enhanced access to affordable cancer treatments.

3. Collaborations and Partnerships: Pharmaceutical companies are increasingly entering strategic collaborations to enhance biosimilar development and commercialization. Partnerships between biotech firms, contract research organizations, and healthcare providers are streamlining market entry and expanding distribution networks.

4. Rising Acceptance Among Physicians: Initial skepticism surrounding biosimilars is gradually fading as real-world evidence demonstrates their safety and efficacy. Educational initiatives and clinical data are fostering confidence among oncologists and patients.

Challenges in the Market

1. Regulatory and Development Complexity: Developing biosimilars involves sophisticated processes and significant investment. Ensuring similarity in structure, function, and clinical outcomes with the reference biologic is challenging and time-consuming.

2. Market Competition: While competition drives innovation, it also exerts pressure on pricing and profitability. Companies must adopt innovative pricing strategies and differentiation approaches to capture market share.

3. Physician and Patient Perception: Despite increasing acceptance, some healthcare providers and patients remain cautious about switching from biologics to biosimilars. Addressing these concerns through education and robust clinical evidence is crucial.

Future Outlook

The oncology biosimilars market is poised for exponential growth, driven by factors like rising cancer prevalence, supportive regulatory frameworks, and ongoing technological advancements. By 2030, the market is expected to reach significant valuations, with Asia-Pacific and emerging markets playing a pivotal role due to their large patient populations and cost-sensitive healthcare systems.

Moreover, advancements in biosimilar manufacturing, including the use of artificial intelligence and machine learning, promise to reduce development timelines and costs. Governments and healthcare organizations worldwide are also likely to continue promoting biosimilar adoption through favorable policies and reimbursement frameworks.

Key Player Analysis:

Allergan (Ireland)

Amneal Pharmaceuticals LLC. (U.S.)

Apotex Inc. (Canada)

Aurobindo Pharma (India)

BIOCAD (Russia)

Bristol-Myers Squibb Company (U.S.)

Cipla Inc. (U.S.)

Eli Lilly and Company (U.S.)

Endo International plc (Ireland)

Hoffmann-La Roche Ltd. (Switzerland)

GlaxoSmithKline plc (U.K.)

Glenmark Pharmaceuticals Limited (India)

Lupin (India)

Mylan N.V. (U.S.)

Novartis AG (Switzerland)

Pfizer Inc. (U.S.)

Sanofi (France)

Sun Pharmaceutical Industries Ltd. (India)

Takeda Pharmaceutical Company Limited (Japan)

Teva Pharmaceutical Industries Ltd.(Israel)

Zydus Cadila (India)

Segmentation:

By Drug

G-CSF

Monoclonal Antibody

Hematopoietic Agents

By Disease Indication

Breast Cancer

Non-Small Cell Lung Cancer

Colorectal Cancer

Neutropenia

Blood Cancer

Leukemia

Myeloid Leukemia

Chronic Lymphocytic Leukemia (CLL)

Non-Hodgkin Lymphoma

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Regional

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/oncology-biosimilars-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: [email protected]

Website: www.credenceresearch.com

0 notes

xinhulian · 3 months ago

Text

What is HER2 and How Does It Relate to Cancer?

The Basics of HER2

HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that is found on the surface of cells and plays a crucial role in cell growth and division. In certain cancers, particularly breast cancer, HER2 can be overexpressed, leading to aggressive tumor growth. Its presence is a significant factor in determining the prognosis and treatment strategies for patients. Understanding the expression of HER2 is vital for effective treatment planning.

The Genetic Mechanism of HER2 Overexpression

HER2 overexpression often results from genetic mutations or amplifications in the HER2 gene located on chromosome 17. These changes lead to the production of excessive HER2 proteins, promoting uncontrolled cell proliferation. The mechanism behind overexpression can vary between individuals, making genetic testing essential to pinpoint specific alterations. Identifying these genetic factors enables clinicians to tailor treatments to target the HER2 pathway effectively.

How Does HER2 Affect Cancer Development?

Mechanisms Leading to Tumor Progression

HER2 activation triggers a cascade of signaling pathways that encourage cell growth, survival, and migration, contributing significantly to tumor progression. This abnormal signaling can lead to heightened aggressiveness in tumor behavior. Notably, tumors that express HER2 often exhibit a higher likelihood of metastasis, making the understanding of its role in cancer development critical for patient management.

Implications of HER2 in Breast Cancer

The relevance of HER2 is particularly pronounced in breast cancer, where approximately 20-25% of cases are HER2-positive. This status is associated with poorer survival rates and more aggressive disease. Awareness of HER2 status not only impacts the prognosis but also informs treatment strategies, including the adoption of targeted therapies that specifically address HER2 signaling pathways.

What Are the Diagnostic Approaches for HER2-Positive Cancers?

Testing Methods for HER2 Status

To determine HER2 status, several testing methods are available, including immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). These tests analyze tumor tissue samples and provide critical insights into the level of HER2 expression or gene amplification. Accurate testing is essential for selecting the appropriate treatment approaches and ensuring optimal patient outcomes.

Interpreting Results and Their Clinical Significance

Interpreting HER2 test results is complex and requires expertise. Positive results indicate the potential for targeted therapies, while negative results might lead to alternative treatment strategies. The clinical significance of these results is immense, as they directly inform patient management decisions and influence prognostic assessments. Clinicians must remain vigilant in reviewing and discussing HER2 status with their patients.

How Can HER2 Status Influence Treatment Decisions?

Personalized Medicine and Targeted Therapies

Herceptin (trastuzumab) and similar agents represent a class of targeted therapies designed for HER2-positive cancers. These therapies work by specifically targeting the HER2 protein, inhibiting its overactive signaling and resulting in reduced tumor growth. The implementation of personalized medicine strategies based on HER2 status has revolutionized treatment protocols, enhancing efficacy for many patients.

Types of Targeted Therapies for HER2-Positive Cancers

In addition to trastuzumab, various other therapies such as pertuzumab and neratinib have emerged as effective options for HER2-positive breast cancer. These treatments can be used as monotherapy or in combination to enhance therapeutic outcomes. Understanding these options enables clinicians to construct individualized treatment plans tailored to specific patient profiles.

Understanding Resistance to HER2-Targeted Treatments

Despite promising outcomes, resistance to HER2-targeted therapies remains a critical challenge. Multiple factors contribute to this resistance, including genetic mutations and alternative signaling pathway activation. Clinicians must consider the possibility of resistance when developing treatment strategies and may need to explore second-line options or combination therapies to overcome this hurdle.

Are There Current Innovations in Treating HER2-Positive Cancers?

Emerging Therapies and Clinical Trials

Current research is focused on investigating novel therapies aimed at improving outcomes for HER2-positive cancer patients. Clinical trials are exploring innovative compounds and combinations that may enhance therapeutic efficacy. Staying abreast of these developments is essential for specialists to provide cutting-edge care.

The Role of Biosimilars in Treatment

Biosimilars are increasingly becoming an integral part of the treatment landscape for HER2-positive cancers, offering cost-effective alternatives to established therapies. The introduction of these agents provides opportunities for better patient access and adherence while maintaining therapeutic equivalence. As biosimilars gain approval, they will likely reshape treatment paradigms.

Solutions for Enhancing Patient Outcomes

Novel Approaches at Celnovte's Solution Center

Exploring additional solutions, such as those available at Celnovte's Solution Center, can enhance patient outcomes in managing HER2-positive cancers. Innovative approaches aiming at improving therapeutic efficacy and addressing treatment challenges are vital as healthcare continues to evolve. Collaborative efforts between specialists and research initiatives are essential for advancing care.

Future Perspectives on HER2 Research and Treatments

Potential Directions for New Therapeutic Strategies

The future of HER2 research lies in discovering novel therapeutic strategies that can address current limitations in treatment. Focused efforts on understanding the biology of HER2-positive tumors will inform the development of more effective therapies. Continuous innovation is crucial to improving patient survival and quality of life.

Collaborative Efforts Needed in Research and Clinical Practice

Collaboration across various disciplines in oncology is critical for advancing HER2 research and the implementation of new treatments. Engaging stakeholders from academic institutions, pharmaceutical companies, and healthcare providers will facilitate the exchange of knowledge and resources necessary to drive progress. These collaborative efforts will ultimately benefit patients and enhance overall cancer care.

celnovte.com

0 notes